Phase III Clinical Trial to Evaluate the Efficacy and Safety of DA-3002 Treatment in Children with Idiopathic Short Stature
Not Applicable
Active, not recruiting
- Conditions
- Endocrine, nutritional and metabolic disease
- Registration Number
- KCT0000896
- Lead Sponsor
- Dong-A ST
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- 64
Inclusion Criteria
Chronological Age = 4
- Bone Age <11 (for girls) and <13 (for boys)
- Height <3rd percentile for age
- normal thyroid function
Exclusion Criteria
- endocrine and/or metabolic disorders
- growth failure caused by other disorders
- previous use of drugs that could interfere with Growth Hormone treatment
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The difference of annualized height velocity between treatment group and non-treatment group after 26 weeks
- Secondary Outcome Measures
Name Time Method Difference of Height Standard Deviation Score between treatment and non-treatment group after 26 weeks